KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aurinia Pharmaceuticals (AUPH) EBT Margin (2018 - 2025)

Historic EBT Margin for Aurinia Pharmaceuticals (AUPH) over the last 9 years, with Q3 2025 value amounting to 43.5%.

  • Aurinia Pharmaceuticals' EBT Margin rose 216600.0% to 43.5% in Q3 2025 from the same period last year, while for Sep 2025 it was 29.96%, marking a year-over-year increase of 391000.0%. This contributed to the annual value of 3.17% for FY2024, which is 473100.0% up from last year.
  • As of Q3 2025, Aurinia Pharmaceuticals' EBT Margin stood at 43.5%, which was up 216600.0% from 31.65% recorded in Q2 2025.
  • Over the past 5 years, Aurinia Pharmaceuticals' EBT Margin peaked at 43.5% during Q3 2025, and registered a low of 5511.05% during Q1 2021.
  • Over the past 5 years, Aurinia Pharmaceuticals' median EBT Margin value was 29.24% (recorded in 2023), while the average stood at 377.47%.
  • Its EBT Margin has fluctuated over the past 5 years, first surged by 1449850000bps in 2021, then plummeted by -97100bps in 2023.
  • Over the past 5 years, Aurinia Pharmaceuticals' EBT Margin (Quarter) stood at 139.28% in 2021, then surged by 36bps to 88.59% in 2022, then skyrocketed by 34bps to 58.58% in 2023, then surged by 103bps to 1.96% in 2024, then skyrocketed by 2120bps to 43.5% in 2025.
  • Its EBT Margin stands at 43.5% for Q3 2025, versus 31.65% for Q2 2025 and 38.98% for Q1 2025.